Yamashita Healthcare Full-Year Financial Results FY2026 | Sales ¥6.41 billion (YoY -0.5%)

Performance Overview

Yamashita Healthcare's fiscal year ending May 2026 recorded sales of ¥64.1 billion (down 0.5% YoY), remaining nearly flat, but net income increased to ¥648 million (+5.1%), driven by strong medical device sales. The profit increase offset decreases in operating income due to rising personnel and system-related expenses, resulting in overall profit growth. Segment-wise, medical device sales are the main segment, supported by increases in testing and surgical procedures, as well as expansion of SPD contracts. Future projections include sales of ¥69.7 billion, operating profit of ¥833 million, and net income of ¥553 million, with continued focus on medical DX and logistics efficiency improvements.

Outlook and Impact on Shareholders

Next fiscal year expects sales to increase, though profits are projected to decrease due to rising personnel and logistics costs. Plans include sales of ¥69.7 billion (+8.8%), operating profit of ¥833 million (+13.1%), and net income of ¥553 million (-14.6%). Dividends, including commemorative dividends, are planned at ¥107 per share (ordinary dividend ¥77 + commemorative ¥30), continuing shareholder returns. In the medium to long term, steady medical demand and DX promotion aim to enhance corporate value.